Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human dose-escalation study of ONO-7914 alone and with ONO-4538 in advanced solid tumors
jRCT2031210530Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ONO-7914 and nivolumab in Nonhematologic neoplasms (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Safety and tolerability. Started Feb 2022; status: completed.
02
Drugs
ONO-7914nivolumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031210530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210530.